Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
A single-arm, multicentre trial to investigate sotorasib in KRASG12C-mutated non-small cell
lung cancer stage III/IV not amenable for curative treatment including patients with
comorbidities, and to provide translational knowledge regarding mechanism of relapse and
differences in responses, including differences among patients with different co-occurring
mutations.
Phase:
Phase 2
Details
Lead Sponsor:
Vestre Viken Hospital Trust
Collaborators:
Aarhus University Hospital Haukeland University Hospital Karolinska University Hospital Odense University Hospital Oslo University Hospital Rigshospitalet, Denmark St. Olavs Hospital University Hospital of North Norway